De-escalation of antiplatelet therapy appears to yield more favourable outcomes compared with standard dual antiplatelet therapy (DAPT) in East Asian patients with acute coronary syndrome (ACS) who are undergoing percutaneous coronary intervention (PCI), as shown in a study.